biOasis Delivers siRNA to the Brain Using its Transcend Peptide Vector

BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), a pioneering
biopharmaceutical company focused on overcoming the limitations of therapeutic
drug delivery across the blood-brain barrier, has shown that a newly discovered
peptide vector form of Transcend - Transcendpep - effectively delivers siRNA
across the blood-brain barrier and into brain cells. This is an exciting
development for potential treatment of a variety of brain disorders. RNA
interference (RNAi) of gene function can be triggered by small single-stranded
RNA molecules (small-interfering RNA; siRNA), which function to silence target
genes in a sequence-specific manner. Therapeutics based on siRNA have been
heralded to have the potential to reverse and eradicate human disease by
targeting specific genes that cause or modify disease outcome. However, since
siRNAs on their own do not cross the blood-brain barrier the targeting of genes
within the brain was not assumed to be achievable. biOasis has now demonstrated
delivery of siRNA across the blood-brain barrier using its new peptide vector,
Transcendpep. After systemic injection, siRNA coupled to Transcendpep was shown
to shuttle into the brain and became localized within brain cells. Since a
variety of different siRNAs (specific for different disease-associated genes)
can be delivered, this is a significant achievement for the Company and for the
field of molecular therapeutics. Transcendpep-siRNA constructs thus become a
potential cornerstone technology for development of new therapeutics for brain
disorders, including, cancers of the brain, Alzheimer's disease, Huntington's
disease, Amyotrophic lateral sclerosis (ALS) and other neuropsychiatric
diseases, and for a variety of neuromuscular diseases, pain, and infections.


"RNAi is a promising and novel therapeutic approach for treatment of many CNS
diseases. The successful delivery of Transcendpep-siRNA conjugates to the brain
is therefore a significant advance and provides the foundation for exploring the
potential of siRNA-based therapeutics for a host of different diseases of the
Central Nervous System," says biOasis Founding Scientist Professor Wilf
Jefferies.


About Transcend & Transcendpep

Transcend and Transcendpep (a family of peptides derived from Transcend) offer
the creation of a new class of drugs that can cross the blood-brain barrier to
address unmet medical needs in the treatment of brain metastatic cancer and
other brain disorders, such as neurodegeneration and metabolic disease. The
blood-brain barrier represents the single greatest challenge in treating
diseases and other disorders within the brain. Diseases such as cancer are
readily treated in many areas of the body, but drugs designed to treat cancer
and other brain disorders simply cannot penetrate the blood- brain barrier. The
ability to more effectively permeate the blood-brain barrier opens the door for
the creation of new drugs designed to treat a wide variety of neurological
diseases and disorders. Additionally, Transcend offers the potential to take
existing clinically approved drugs that are near their end of patent life and
extend them.


About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the OTCQX under the symbol BIOAF and on the TSX Venture
Exchange under the symbol "BTI". For more information about the company please
visit www.bioasis.ca.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not succeed in
preclinical or clinical trials, or future products in our targeted corporate
objectives; our future operating results are uncertain and likely to fluctuate;
we may not be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching our products
may be greater than anticipated; we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual property
matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given these risks
and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and
information made herein are based on our current expectations and we undertake
no obligation to revise or update such forward- looking statements and
information to reflect subsequent events or circumstances, except as required by
law.


On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
778-383-3280
rob@bioasis.ca


Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Senior Managing Director
949-574-3860
BTI@liolios.com
BiOasis Technologies (TSXV:BTI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024